SFI
GMAB icon

Susquehanna Fundamental Investments’s Genmab GMAB Stock Holding History

Susquehanna Fundamental Investments’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-19,371
Closed -$736K – 467
2023
Q2 		$736K Hold
19,371
– – 0.03% 386
2023
Q1 		$731K Sell
19,371
-7,497
-28% -$288K 0.02% 592
2022
Q4 		$1.14M Hold
26,868
– – 0.02% 620
2022
Q3 		$863K Buy
+26,868
New +$943K 0.01% 849

Other funds holding GMAB

AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
1832 Asset Management
1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Susquehanna Fundamental Investments's GMAB Position: Q3 2023 in Review

Susquehanna Fundamental Investments sold out of Genmab (GMAB) in Q3 2023, closing a stake of 19,371 shares — an estimated $736K sold.

Susquehanna Fundamental Investments first reported a position in GMAB in Q3 2022 and held it in 4 quarters. The position peaked at $1.14M in Q4 2022. 234 funds tracked by Wall St. Rank hold GMAB as of Q3 2023.

  • Susquehanna Fundamental Investments reported no remaining Genmab position as of Q3 2023 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 19,371 Genmab shares in Q3 2023, an estimated $736K.
  • Susquehanna Fundamental Investments first reported a position in Genmab in Q3 2022 and held it in 4 quarters.
  • Susquehanna Fundamental Investments's Genmab position peaked at $1.14M in Q4 2022.
  • 234 funds tracked by Wall St. Rank held Genmab as of Q3 2023.

Based on Susquehanna Fundamental Investments's 13F filing for Q3 2023, filed 14 Nov 2023.